Latest results from clinical trials with trastuzumab deruxtecan (brand name: Enhertu) have shown significant benefits for two groups of patients with advanced breast cancer: those with high levels
BCAC sends huge congratulations to former Committee Member Irene Kereama-Royal who has been awarded a scholarship by Hei Āhuru Mōwai (Māori Cancer Leadership Aotearoa) an
Knowing our genetic risk of diseases such as BRCA-related breast cancer can be lifesaving, but New Zealand insurance companies can use this knowledge to discriminate agai